NASDAQ · CINGHealthcarePharmaceuticals

Cingulate financials

$4.91+1.76%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Gross margin—————
Operating income-$19.9M-$15.6M-$22.8M-$17.5M-$20.7M
Net income-$22.4M-$16.6M-$23.5M-$17.7M-$20.7M
Net margin—————
Diluted EPS$-4.44$-10.86$-311.99$-352.20$-669.60
EBITDA-$19.4M-$15.0M-$22.2M-$17.1M-$20.0M
Operating cash flow-$17.2M-$18.5M-$15.0M-$15.9M-$10.4M
Free cash flow-$17.4M-$18.7M-$15.3M-$16.0M-$11.2M
Diluted shares5.1M1.5M0.1M0.1M0.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$11.0M$12.2M$52.4K$5.4M$16.5M
Short-term investments$0.00$0.00$0.00$0.00$933.00
Total debt$7.4M$5.0M$3.0M$5.0M$52.6K
Total assets$15.1M$14.9M$3.5M$11.4M$22.9M
Total liabilities$12.6M$7.4M$10.4M$7.5M$2.0M
Shareholders' equity$2.5M$7.5M-$6.9M$3.9M$20.8M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology